CHDArrhythmiasDiabetesLipidologyHeart FailureHypertensionStrokeThrombosis
Log in
Username
Password
Remember me
Bookmark this site|Register Me|Forgotten Password
Welcome to InCirculation.net
InCirculation.net is a professional cardiovascular resource intended for a global audience of specialists, generalists, researchers, and other healthcare professionals 		Would you like to know what else InCirculation.net has to offer? Take the tour of InCirculation.net
Click here to register

What's New

 print this page   back


Page summary
Text size
Search
What’s New keeps you up-to-date with the latest InCirculation.net activities.
 





24 August 2010
REAL/ZEST-LATE: dual platelet therapy essential for early treatment of acute coronary syndrome but questionable in the long-term
By: Freek W.A. Verheugt

Dual antiplatelet therapy is the cornerstone of the treatment of acute coronary syndromes with or without stent implantation, but what is the optimal duration of this therapy? Freek Verheugt discusses long-awaited data from two randomized studies – REAL-LATE and ZEST-LATE – that go some way to answering this question.



10 August 2010
RE-LY: Dabigatran treatment of atrial fibrillation promising in the prevention of stroke
By: A. John Camm

RE-LY showed conclusively that treatment with dabigatran significantly reduces stroke risk in comparison with warfarin in patients with atrial fibrillation and at least one risk factor. John Camm presents the data and discusses the implications of this landmark study.




4 May 2010
BARI 2D – Aid to the management of diabetic coronary disease or flawed trial?
By: Akhil Kapur and Katie Qureshi

Five-year results from the BARI 2D trial suggest that optimal medical therapy is a reasonable first-line strategy for the treatment of low-risk patients with diabetes and limited coronary disease. Akhil Kapur and Katie Qureshi review the broad-ranging implications of the trial.





1 ...  2  3  4  ... 16  next 
 Section feedback  Send to a friend 
 Top of page
All rights reserved. This website is intended for an international audience. Privacy PolicyLegal NoticeTerms and Conditions